Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04174157 · ClinicalTrials.gov registry record
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A clinical trial of Spinal Muscular Atrophy (SMA), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- 700
- Enrollment target
- 20
- Study locations
NCT04174157 is a study of Spinal Muscular Atrophy (SMA) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 700 participants, above the 143-participant average among 5 other Spinal Muscular Atrophy (SMA) trials with a reported enrollment target (390% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT04174157, a study of Spinal Muscular Atrophy (SMA), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
Conditions Studied
Interventions
- OTHER Prospective observational registry
- DRUG Zolgensma
Study Locations (20)
California
- Loma Linda University Health - Loma Linda
- Children's Hospital of Los Angeles - Los Angeles
- University of California Los Angeles Health - Los Angeles
- Valley Children's Healthcare - Madera
- Children's Hospital of Orange County - Madera
- University of California Davis Health System - Sacramento
- Rady Children's Hospital San Diego - San Diego
Florida
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- Nicklaus Children's Hospital - Miami
- Adventist Health System - Florida - Orlando
- Jackson South Medical Center - Palmetto Bay
Connecticut
- Connecticut Children's Medical Center - Farmington
- Yale-New Haven Health System - New Haven
Arizona
- Phoenix Children's Hospital - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Indiana
- Indiana University Health University Hospital (IUHUH) - Indianapolis
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2018-09-25 |
| Est. Completion | 2038-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04174157
The ClinicalTrials.gov registry entry for NCT04174157 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 143-participant average among 5 other Spinal Muscular Atrophy (SMA) trials with a reported enrollment target (390% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Spinal Muscular Atrophy (SMA) appearing as the primary indexed condition, and to 2 interventions - of which Prospective observational registry is the first listed.
NCT04174157 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04174157 about?
NCT04174157 is a clinical study titled "Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)". Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an ...
What is the current status of trial NCT04174157?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2018-09-25. Estimated completion is 2038-06-30.
What conditions does trial NCT04174157 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy (SMA).
What interventions are being tested in trial NCT04174157?
The interventions under investigation include: Prospective observational registry (OTHER), Zolgensma (DRUG).
Who is sponsoring clinical trial NCT04174157?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04174157 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy (SMA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health System
RECRUITING
-
HABIT-ILE + FST in Children With SMA: Preliminary Effectiveness
RECRUITING · NA
-
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.